Biopsy‐free screening for glioma. Issue 12 (6th November 2018)

• Record Type: Journal Article
• Authors: Cheng, Alexandre Pellan; Burnham, Philip; De Vlaminck, Iwijn
• Is Part Of: EMBO molecular medicine. Volume 10:Issue 12(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-11-06
• Subjects: Molecular biology -- Periodicals; Medical genetics -- Periodicals; Pathology, Molecular -- Periodicals; 616.04205
• DOI: 10.15252/emmm.201809484
• Languages: English
• ISSNs: 1757-4676

Abstract

Abstract : Circulating tumor DNA (ctDNA) is a promising diagnostic marker for many cancers and can be noninvasively assayed from blood. For diagnosing glioma, this approach has unfortunately proven to be of limited use since glioma contribute minimal ctDNA to the blood circulation. A more promising avenue may therefore be to hunt for ctDNA in cerebrospinal fluid (CSF). The study by Mouliere et al in this issue of EMBO Molecular Medicine demonstrates that shallow whole‐genome sequencing of CSF‐cfDNA can be used to detect copy number alterations in glioma‐derived ctDNA, providing a low cost strategy to screen for glioma. Abstract : De Vlaminck & colleagues discuss the low‐cost screening strategy developed by Mouliere et al (in this issue of EMBO Molecular Medicine ) that takes advantage of shallow whole‐genome sequencing of tumor‐derived cell‐free DNA in the cerebrospinal fluid to identify gliomas.